CEPI

Close up of vaccine syringe
#CEPI #Ebola virus #Immunology / Virology & Vaccines #Outbreak

CEPI backs Minapharm’s Bundibugyo ebolavirus vaccine candidate

African biopharmaceutical company Minapharm Group will receive up to $16.5 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of a Bundibugyo ebolavirus vaccine candidate.  The investment is part of efforts to develop vaccines to combat the fastest-growing and second-largest Ebola outbreak on… Read More

#News #Trending News

Ebola outbreak
#CEPI #Ebola virus #Immunology / Virology & Vaccines #Moderna #Outbreak

Phase I trial “a major step forward” against Ebola outbreak

Following Health Canada’s authorisation, the first participants have been vaccinated in Moderna’s Phase I clinical study evaluating mRNA-1469, an mRNA vaccine to prevent Bundibugyo ebolavirus (BDBV).  “Vaccinating the first participants with mRNA-1469 marks an important milestone in advancing a vaccine candidate against Bundibugyo ebolavirus, for which no… Read More

#Editor's Choice #News #Trending News

mRNA
#CEPI #Immunology / Virology & Vaccines #Influenza #Moderna #mRNA #Pandemic prevention #Pandemic response

$54.3m CEPI investment boosts Moderna’s H5 influenza vaccine

The Coalition for Epidemic Preparedness Innovations (CEPI) is to invest up to $54.3 million to support a pivotal Phase III clinical trial that aims to help advance Moderna’s investigational mRNA-based H5 pandemic influenza vaccine candidate, mRNA-1018, to licensure.   The organisation says the funding marks a significant step… Read More

#Business & Investment #News

Monkeypox virus
#CEPI #Immunology / Virology & Vaccines #Pandemic prevention #Vaccines

Immune marker playbooks support vaccine development

CEPI and PATH are joining forces to create playbooks that map all available research into specific immune markers that indicate protection against target viruses with epidemic or pandemic potential.  Supported by $8 million in funding from CEPI, these research and development (R&D) manuals could hold important insights… Read More

#News

#Adaptvac #CEPI #Disease X #Ebola virus #Immunology / Virology & Vaccines #Pandemic prevention

All-in-one vaccine development backed by $12.4m funding

Scientists at Denmark’s Adaptvac will lead the development of a new vaccine that could provide all-in-one protection against multiple deadly viruses, including Ebolavirus Zaire, Sudan Ebolavirus and Marburg.  Backed by $12.4 million of funding from CEPI and the European Union’s Horizon Europe programme, a global consortium led… Read More

#Editor's Choice #News

Patient receiving vaccine
#CEPI #Immunology / Virology & Vaccines #Nipah Virus #Pandemic prevention #University of Oxford

In-human trial begins for first potential Nipah virus vaccine

The first clinical trial participants have received doses of the ChAdOx1 NipahB vaccine at the University of Oxford. Nipah virus is mostly found in South-East Asia that can be fatal in up to 75% of cases. Despite the first outbreaks occurring 25 years ago in… Read More

#News

Doctor prepares vaccine
#Barinthus Biotherapeutics #CEPI #Immunology / Virology & Vaccines #Partnership #University of Oxford

Partnership to fast-track MERS vaccine

UK-based Barinthus Biotherapeutics, the Coalition for Epidemic Preparedness Innovations (CEPI) and the University of Oxford are working together to fast-track the development of a vaccine candidate for the prevention of Middle East Respiratory Syndrome (MERS). The partners plan to take a MERS vaccine from early development… Read More

#Business & Investment #News